Results 61 to 70 of about 7,465 (255)

The Plexiform Neurofibroma Microenvironment [PDF]

Cancer Microenvironment, 2012
Dynamic interactions between tumorigenic cells and surrounding cells, including immunomodulatory hematopoietic cells, can dictate tumor initiation, progression, and transformation. Hematopoietic-stromal interactions underpin the plexiform neurofibroma, a debilitating tumor arising in individuals afflicted with Neurofibromatosis type 1 (NF1), a common ...
Feng-Chun, Yang, Karl, Staser, D Wade, Clapp   +2 more
openaire   +2 more sources

Plexiform Neurofibroma Involving the Lacrimal Gland

Case Reports in Ophthalmology, 2017
Background: To present a rare case of a 2-year-old girl with neurofibromatosis type 1 (NF1) who presented with ptosis of the right upper eyelid along with a tumor in the eyelid.
Mikael Hofsli, Nico Gampenrieder, Steffen Heegaard   +2 more
doaj   +1 more source

TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]

, 2019
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang, Godec, Abigail, Hirbe, Angela C, Qin, Wenjing, Shao, Jieya, Tao, Yu, Zhang, Xiaochun, Zhu, Cuige   +7 more
core   +2 more sources

Neurodevelopmental and Psychiatric Studies in Children and Adolescents With Neurofibromatosis Type I: A Comprehensive Scoping Review

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 201, Issue 4, Page 257-269, June 2026.
ABSTRACT A comprehensive synthesis of the broad range of neurodevelopmental and psychiatric manifestations in NF1 is needed to identify knowledge gaps and future directions for NF1 research. In the following scoping review, we identify and summarize the scope of research that examines neurodevelopmental and psychiatric manifestations, both as ...
Meera Chopra, Tin‐Suet Joan Lee, Jacob Vorstman, Patricia Parkin, Louise Gallagher, Aneta Krakowski   +5 more
wiley   +1 more source

Plexiform Neurofibroma of Face: A Challenge for Plastic Surgeons

Journal of the Dow University of Health Sciences, 2009
Plexiform neurofibroma is a benign tumour of peripheral nerves and connective tissue. They developmost often in patients with neurofibromatosis type 1 (NF1) and often grow continuously.
Muhammad Ahmad, Saleem A. Malik
doaj   +4 more sources

Occlusal traits in children with neurofibromatosis type 1 [PDF]

, 2015
Literature is poor of data about the occlusion in children affected by neurofibromatosis type 1 (NF1).
Amadori, F, Bardellini, E, Flocchini, P, Majorana, A, Micheli, R, Molinaro, A, Piana, G, Tonni, I   +7 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Solitary Plexiform Neurofibroma of the Gingiva: Unique Presentation in the Oral Cavity [PDF]

Journal of Clinical and Diagnostic Research, 2013
Neurofibromas are benign tumours originating from the nerve sheath. Amongst the histological variants, plexiform types are considered exclusive. These are poorly circumscribed, locally invasive and may exhibit sarcomatous potential.
SURAMYA S., PRATIBHA SHASHIKUMAR, SHREESHYLA H.S., SHEELA KUMAR G.   +3 more
doaj   +1 more source

Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1microdeletions [PDF]

, 2012
BACKGROUND: Neurofibromatosis type-1 (NF1) is caused by mutations of the NF1 gene at 17q11.2. In 95% of non-founder NF1 patients, NF1 mutations are identifiable by means of a comprehensive mutation analysis. 5-10% of these patients harbour microdeletions
David N Cooper, Hildegard Kehrer-Sawatzki, Josef Högel, Lan Kluwe, Rosa Nguyen, Tanja Mußotter, Victor-Felix Mautner   +6 more
core   +2 more sources

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, Volume 16, Issue 4, Page 803-813, April 2026.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source